- Home
- GLUE
as of 03-12-2026 3:59pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.4B | IPO Year: | 2021 |
| Target Price: | $29.50 | AVG Volume (30 days): | 777.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $25.77 | Next Earning Date: | N/A |
| Revenue: | $75,622,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 84.02% | Revenue Growth (next year): | -59.16% |
| P/E Ratio: | 72.42 | Index: | N/A |
| Free Cash Flow: | 38.0M | FCF Growth: | N/A |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
Principal Accounting Officer
Avg Cost/Share
$17.96
Shares
139
Total Value
$2,496.44
Owned After
22,554
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$17.50
Shares
536
Total Value
$9,380.00
Owned After
22,554
SEC Form 4
President & CEO
Avg Cost/Share
$17.92
Shares
5,466
Total Value
$97,974.22
Owned After
613,471
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$18.10
Shares
25,164
Total Value
$455,506.15
Owned After
22,554
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$19.50
Shares
9,189
Total Value
$179,160.69
Owned After
65,837
SEC Form 4
President & CEO
Avg Cost/Share
$23.90
Shares
5,466
Total Value
$128,372.57
Owned After
613,471
Chief Medical Officer
Avg Cost/Share
$15.17
Shares
3,155
Total Value
$47,861.35
Owned After
65,837
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$15.17
Shares
1,039
Total Value
$15,761.63
Owned After
22,554
SEC Form 4
President & CEO
Avg Cost/Share
$15.17
Shares
10,135
Total Value
$153,747.95
Owned After
613,471
SEC Form 4
Chief Business & Legal Officer
Avg Cost/Share
$15.17
Shares
3,155
Total Value
$47,861.35
Owned After
60,845
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dunn Edmund | GLUE | Principal Accounting Officer | Mar 4, 2026 | Sell | $17.96 | 139 | $2,496.44 | 22,554 | |
| Dunn Edmund | GLUE | Principal Accounting Officer | Mar 2, 2026 | Sell | $17.50 | 536 | $9,380.00 | 22,554 | |
| Warmuth Markus | GLUE | President & CEO | Mar 2, 2026 | Sell | $17.92 | 5,466 | $97,974.22 | 613,471 | |
| Dunn Edmund | GLUE | Principal Accounting Officer | Feb 27, 2026 | Sell | $18.10 | 25,164 | $455,506.15 | 22,554 | |
| Janku Filip | GLUE | Chief Medical Officer | Feb 23, 2026 | Sell | $19.50 | 9,189 | $179,160.69 | 65,837 | |
| Warmuth Markus | GLUE | President & CEO | Jan 7, 2026 | Sell | $23.90 | 5,466 | $128,372.57 | 613,471 | |
| Janku Filip | GLUE | Chief Medical Officer | Jan 5, 2026 | Sell | $15.17 | 3,155 | $47,861.35 | 65,837 | |
| Dunn Edmund | GLUE | Principal Accounting Officer | Jan 5, 2026 | Sell | $15.17 | 1,039 | $15,761.63 | 22,554 | |
| Warmuth Markus | GLUE | President & CEO | Jan 5, 2026 | Sell | $15.17 | 10,135 | $153,747.95 | 613,471 | |
| Nickson Philip | GLUE | Chief Business & Legal Officer | Jan 5, 2026 | Sell | $15.17 | 3,155 | $47,861.35 | 60,845 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 6, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 6, 2025 · 100% conf.
1D
+3.34%
$13.64
Act: -6.74%
5D
+13.53%
$14.99
Act: +8.48%
20D
+12.51%
$14.85
Act: +31.89%
8-K
0001826457false00018264572025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
MONTE ROSA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40522
84-3766197
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
321 Harrison Avenue, Suite 900 Boston, MA 02118 (Address of principal executive offices, including zip code) (617) 949-2643 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
GLUE
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On November 6, 2025, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 7.01. Regulation FD Disclosure On November 6, 2025, the Company posted a revised presentation to the "Presentations" section of the Company's website at https://www.monterosatx.com/. The information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits
99.1
Press Release issued by Monte Rosa Therapeutics, Inc. dated November 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Monte Rosa Therapeutics, Inc.
Date: November 6, 2025
By:
/s/ Markus Warmuth
Markus Warmuth
President and Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
8-K
false000182645700018264572025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025
MONTE ROSA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40522
84-3766197
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
321 Harrison Avenue, Suite 900 Boston, MA 02118 (Address of principal executive offices, including zip code) (617) 949-2643 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
GLUE
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On August 7, 2025, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits
99.1
Press Release issued by Monte Rosa Therapeutics, Inc. dated August 7, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Monte Rosa Therapeutics, Inc.
Date: August 7, 2025
By:
/s/ Markus Warmuth
Markus Warmuth
President and Chief Executive Officer
2025 Q1 Q1 2025 Earnings
8-K May 8, 2025
Q1 2025 Earnings
8-KMay 8, 2025
8-K
0001826457false00018264572025-05-082025-05-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025
MONTE ROSA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40522
84-3766197
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
321 Harrison Avenue, Suite 900 Boston, MA 02118 (Address of principal executive offices, including zip code) (617) 949-2643 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
GLUE
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On May 8, 2025, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 7.01. Regulation FD Disclosure On May 8, 2025, the Company issued a corporate presentation that it intends to utilize in various meetings with securities analysts, investors and others. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information under Item 2.02 and Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits
99.1
Press Release issued by Monte Rosa Therapeutics, Inc. dated May 8, 2025.
99.2
Corporate presentation furnished by Monte Rosa Therapeutics, Inc. on May 8, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Monte Rosa Therapeutics, Inc.
Date: May 8, 2025
By:
/s/ Markus Warmuth
Markus Warmuth
President and Chief Executive Officer
Compare GLUE vs Leading Stocks
See how GLUE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.